Puma Biotech Makes Big Breakthrough In Breast Cancer Treatment

Puma Biotech Makes Big Breakthrough In Breast Cancer Treatment


Shares of Puma Biotechnology Inc soared higher by more than 70 percent on Monday after the U.S. Food and Drug Administration posted briefing documents ahead of the regulatory body's review of Puma's PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer, which is scheduled for Wednesday. The FDA's Oncologic Drugs Advisory Committee is an independent panel of experts that evaluates data relating to the safety and efficacy of investigational cancer treatments.



from Biotech News